The Carlyle Group related stories
All articles and analysis
Women of Influence: Private debtOur new program spotlights women whose achievements, innovation and leadership are reshaping private markets across a broad range of asset classes.
Women of Influence: Private equityOur new program spotlights women whose achievements, innovation and leadership are reshaping private markets across a broad range of asset classes.
PERE 100 returns bolstered in a turbulent yearAided by the rise of logistics and other property types, opportunistic and value-add managers outperformed their core counterparts.
How Carlyle’s Metropolitan sale deviated from the pastThe private equity giant took a different exit route in splitting from its indirect real estate platform than other sub-scale businesses in recent years.
TCRS approves $100m commitment to Carlyle Realty Partners IXThe US public pension has re-upped with the Carlyle Group.
Blueprint: PERE's Proptech 20 launches; KKR's $1bn life sciences deal; Ares's Landmark purchase analyzed; BGO's diversity winPERE’s Proptech 20 ranking launches; KKR plunges into life sciences with a $1 billion deal; further insights into Ares’s purchase of secondaries specialist Landmark Partners; the diversity benefits for BGO in acquiring Metropolitan Real Estate; and more in today's briefing, exclusively for our valued subscribers.
Distressed debt deals are still the exception rather than the normOaktree’s substantial deployment of its latest property fund is not indicative of dealflow in the market overall, but rather that it is ahead of the pack.
What BentallGreenOak’s Metropolitan deal says about secondariesThe New York-based secondaries specialist’s trade from Carlyle to BGO highlights the benefits and risks involved with investing in the space.
Blueprint: GameStop's impact on real estate, WeWork's SPAC ambitions, the emergence of listed real estateThe emergence of listed real estate in institutional portfolios; how the ripple effects of GameStop's big week have touched mall REITs; WeWork's latest run at the public markets; and more in today's briefing, exclusively for our valued subscribers.
What Blackstone's $3.45bn deal says about life science pricingAt 2.3m square feet, the research lab and office portfolio purchased from Brookfield is the largest to trade hands this year. But is it worth the price?